瑞舒伐他汀对脑出血患者的血浆组织因子和组织因子途径抑制物的影响

Effect of Rosuvastatin on Plasma Tissue Factor and Tissue Factor Pathway Inhibitor in Patients with Hematencephalon

关键词:  瑞舒伐他汀  脑出血  血浆组织因子  组织因子途径抑制物

Key words:  rosuvastatin  hematencephalon  plasma tissue factor  tissue factor pathway inhibitor

摘要:

目的 观察瑞舒伐他汀对脑出血患者血浆组织因子（tissue factor，TF）和组织因子途径抑制物（tissue factor pathway inhibitor，TFPI）的影响。方法 选择2015年1月-2016年1月住院的100例脑出血患者作为病例组，同期选取体检的100名健康受试者作为正常组。将病例组患者随机分为观察组（51例）和对照组（49例）。对照组术后给予常规治疗，如调控血压和脑水肿、调节磷钙代谢、甘露醇静滴等；观察组在此基础上口服瑞舒伐他汀片20 mg治疗，每天1次，持续3个月。比较病例组和正常组血浆TF和TFPI水平；并比较观察组和对照组治疗前后TF、TFPI和血脂水平变化情况。结果 治疗前，病例组TF和TFPI水平高于正常组，差异有统计学意义（P<0.05）。治疗前，观察组和对照组的TF、TFPI和血脂水平进行比较，差异无统计学意义；治疗3个月后，观察组TF水平明显低于对照组，TFPI水平明显高于对照组，差异均有统计学意义（P<0.05）。Pearson相关性分析表明TF或TFPI与血脂水平（甘油三酯、总胆固醇、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇）无相关性。观察组和对照组不良反应率比较，差异无统计学意义。结论 瑞舒伐他汀治疗术后脑出血患者，能够降低TF水平，提高TFPI水平，对于纠正脑出血患者凝血功能紊乱具有重要意义。

Abstract:

OBJECTIVE To observe the effect of rosuvastatin on plasma tissue factor (TF) and tissue factor pathway inhibitor(TFPI) in patients with hematencephalon. METHODS One hundred patients with cerebral hemorrhage from January 2015 to January 2016 were enrolled as case group, and a total of 100 healthy persons were selected as normal group at the same time. The patients were randomly divided into observation group (51 cases) and control group (49 cases). The control group was given routine treatment such as to improve blood press and encephaledema, to adjust metabolic system of phosphorus and calcium, to drip mannitol in intravenous after treatment. The observation group was given rosuvastatin (p.o 20 mg, qd, last for 3 month) on the basis of control group. Levels of TF and TFPI were compared between case group and normal group before treatment, and levels of TF, TFPI and serum lipid were compared between control group and observation group before and after treatment. RESULTS The levels of TF and TFPI in case group were significantly higher than those in normal group before treatment. The levels of TF, TFPI and serum lipid in observation group were not significantly different from those in control group before treatment. After treatment for 3 months, the levels of TF in observation group were significantly lower than those in control group; the levels of TFPI in observation group were significantly higher than those in control group. Correlation analysis of Pearson indicated that there were no correlation between the level of TF or TFPI with serum lipid levels. There was no significantly different in adverse reaction rates between observation group and control group. CONCLUSION Rosuvastatin could decrease the levels of TF and increased the level of TFPI in patients with hematencephalon. Therefore, rosuvastatin could balance coagulation for patients with hematencephalon.